By K. Boss. College of Saint Joseph. 2018.
Proton pump inhibitors Page 76 of 121 Final Report Update 5 Drug Effectiveness Review Project 57 purchase kamagra soft 100 mg on-line. Comparison of omeprazole with ranitidine in the treatment of reflux oesophagitis discount kamagra soft 100 mg with mastercard. Scandinavian Journal of Gastroenterology - Supplement. Omeprazole produces significantly greater healing of erosive or ulcerative reflux oesophagitis than ranitidine. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Armstrong D, Pare P, Pericak D, Pyzyk M, Canadian Pantoprazole GSG. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy- negative reflux disease. Dettmer A, Vogt R, Sielaff F, Luhmann R, Schneider A, Fischer R. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Koop H, Schepp W, Dammann HG, Schneider A, Luhmann R, Classen M. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Meneghelli UG, Boaventura S, Moraes-Filho JP, et al. Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Proton pump inhibitors Page 77 of 121 Final Report Update 5 Drug Effectiveness Review Project 70. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease a double blind, randomized clinical trial. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Goh K-L, Benamouzig R, Sander P, Schwan T, Emancipate. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. Monnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Proton pump inhibitors Page 78 of 121 Final Report Update 5 Drug Effectiveness Review Project 83. Vivian E, Morreale A, Boyce E, Lowry K, Ereso O, Hlavin P.
Typical signs of indinavir nephropathy include sterile leukocyturia with loss of renal function (Gagnon 2000 generic kamagra soft 100mg mastercard, Dielemann 2003) and an echogenic transformation of the renal parenchyma in otherwise normal kidneys kamagra soft 100 mg low price. Discontinuing indinavir leads to normal function in most cases. Tuberculosis in the urinary tract with sterile leukocyturia should be considered. HIV and Renal Function 579 Hypophosphatemia, tubulotoxic damage, Fanconi’s syndrome Alongside glomerular filtration of substances such as creatinine, an alternative form of secretion via transporters in the tubulus is possible. In the proximal tubulus, the transporter OCT2 leads to an intake of creatinine from the the blood in the tubular cell, which in turn is secreted into the urine via MATE 1. The integrase inhibitor dolutegravir inhibits OCT2, whereas the pharmacoenhancer cobicistat inhibits MATE 1. Thus, both substances block the alternative secretion route via the tubular cells, which leads to a slight increase in creatinine (0. Of course, this does not change the true GFR and therefore has no effect on the glomerulus or the renal function. Tivicay can thus also be used in patients with limited kidney function. However, care must be taken regarding the combination with TDF, as it may be difficult to identify a true impairment of renal function, and TDF must be reduced in cases of a GFR of less than 60 ml. The fixed- dose combination Stribild should thus only be used in patients with an eGFR >90 ml and should be avoided below 70 ml. Tenofovir itself is absorbed into the tubular cell not only via glomerular filtration but also via the transporter OAT 1 and is then secreted actively (dependent on ATP) via MRP 2 and 4 into the urine of the proximal tubulus. Should true filtration in the glomerulus decline (for example, in cases of acute kidney failure), attempts are made to eliminate more TDF via the tubular cell (increased activity of OAT 1). This results in an increased concentration of TDF in the tubular cell, which in turn leads via a disruption of the mitochondrial polymerase gamma to a decline in energy-depen- dent MRP 2 and 4 transport capacity and can thus end in tubular damage (Perazella 2010). Indeed, concentration-dependent damage caused by TDF to the tubular cell can be demonstrated: patients with low body weight are more vulnerable (Nishijirna 2012). When the agents filtered from the glomerulus in primary urine exceed the transport capacity of the reabsorbing tubular cells they are excreted with the urine. The most prominent example is the glucose threshold of the kidneys (180 mg/dl). However, a transport dysfunction in the tubular system can also be caused by drugs such as cidofovir, tenofovir and adefovir. This is known as secondary (drug-induced) Fanconi’s syndrome and is distinguished by a malfunction of the tubular system without there necessarily being any impairment of the GFR. There is an increased amount of phosphate, amino acids and glucose in the urine, whereas phosphate in the blood is reduced. The loss of amino acids, phosphate, glucose, bicarbonate and other organic and inorganic substances, as well as water, can become clinically manifest in the form of increased urination, thirst, tiredness, bone pain or weakness, and lead to secondary changes in the bone metabolism. Special caution is required when dealing with fixed-dose combinations (FDCs) such as Stribild. This also includes determination of blood sugar, potassium in the blood and glucose concentration in the urine. In patients whose creatinine clear- ance is confirmed to drop to <50 ml/min or whose serum phosphate level drops to 1. Hypophosphatemia also occurs under the influence of alcohol, with diabetes, cachexia, diarrhea or a disorder of vitamin D metabolism or hyperparathyroidism. About 10% of cases are found in untreated HIV+ patients, 23% in people on ART and up to 31% in those taking tenofovir. The reasons are many and varied, includ- 580 Interdisciplinary Medicine ing a low phosphate absorption (normal: 1200 mg/day). The determination of intact parathormone, vitamin D or an anamnesis with diuretics, vomiting or a tumor may indicate other causes of hypophosphatemia. The secretion ratio of phosphate to creatinine can be a sign of tubular damage if, despite hypophosphatemia, more that 10% of the filtrated phos- phate is secreted (Jamison 1982). Secretion ratio: (urine phosphate, mg/dl) x (serum creatinine, mg/dl) (serum phosphate, mg/dl) x (urine creatinine, mg/dl) In case reports, renal failure has above all been described in patients with other reasons for renal insufficiency, mostly in ART combinations that include boosted PI regimens and tenofovir as well as secondary disorders and cirrhosis of the liver or hepatitis. Nephrologists advise caution in selecting antiretroviral therapy for patients with proteinuria, nephritic syndrome, cirrhosis of the liver, and/or dyslipoproteine- mia. Potentially nephrotoxic agents such as cidofovir, adefovir, tenofovir or fixed- dose combinations should be avoided in these patients. In principle, it is possible to administer NRTIs (e. Renal insufficiency and ART In advanced cases (with appropriate resistance testing), NRTI-sparing combinations of a PI/r plus raltegravir, two boosted PIs, a combination of an NNRTI plus a PI or combinations of dolutegravir or maraviroc can be considered as kidney-neutral solu- tions. Careful monitoring of serum creatinine, proteinuria, erythrocyturia and serum phosphate is recommended. Tenofovir and the kidney In view of the broad use of tenofovir, more attention must be devoted to long-term renal toxicity in the future. The increased renal risk observed in early cohort studies was less explicit in more recent analyses – possibly because TDF is now being used more carefully by the treating physicians. Studies verified an increased tubular risk with TDF (Dauchy 2011) higher than that with ABC+3TC (Moyle 2010).
Olanzapine was only studied in combination with fluoxetine and compared with fluoxetine discount 100mg kamagra soft otc, olanzapine discount 100mg kamagra soft fast delivery, nortriptyline, and venlafaxine monotherapies. Ziprasidone was only studied in combination with sertraline and compared with sertraline monotherapy. Therefore, the evidence for olanzapine and ziprasidone applies to more limited situations than the evidence for aripiprazole, extended- release quetiapine, immediate-release quetiapine, and risperidone. Likewise, in the longer-term trial of risperidone augmentation, it was only studied in combination with citalopram and, thus, 441 has limited applicability. Placebo-controlled trials of atypical antipsychotic monotherapy were only found for 452 448-451, 453, 454 immediate-release quetiapine and extended-release quetiapine. Additionally, all patients in the trial of immediate-release quetiapine were undergoing 452 weekly sessions of cognitive behavioral therapy. In 2 shorter-term trials of extended-release 454 453, 454 quetiapine, participants were randomized to fixed dosages of 50 mg, 150 mg, or 300 453, 454 mg. In the remaining shorter-term trials, including the trials in adults with a mean age of 451 71. After 2 weeks, participants with an inadequate response were titrated to 300 mg. Similarly, in a longer-term trial, monotherapy with extended-release Atypical antipsychotic drugs Page 104 of 230 Final Report Update 3 Drug Effectiveness Review Project 450 quetiapine was initiated at 50 mg and titrated to 150 mg after 3 to 4 days. Dosages were then adjusted to 50 mg, 150 mg, or 300 mg based on clinical judgment. Effectiveness Relapse prevention Monotherapy Extended-release quetiapine is distinguished as the only atypical antipsychotic to have any long- term evidence of efficacy as monotherapy maintenance treatment from a controlled trial (52 450 weeks). In an unpublished trial provided by the manufacturer, the effectiveness of maintenance monotherapy with flexibly-dosed extended-release quetiapine (50 mg to 300 mg, mean not reported) was evaluated in 776 of 1854 (42%) adults with major depressive disorder, single episode or recurrent, who responded to open-label acute treatment (4-8 weeks) with extended-release quetiapine (MADRS score of 12 or below or a CGI-S score of 3 or below). Compared with placebo, rates of relapse were significantly lower for extended-release quetiapine monotherapy (14% compared with 34%; hazard ratio, 0. We found one trial that evaluated whether continuation treatment with risperidone plus citalopram provided greater maintenance of effect than a return to citalopram 441 monotherapy (Augmentation with Risperidone in Resistant Depression, ARISe-RD). This trial enrolled adults who had experienced resistance to standard antidepressant therapy during their current depressive episode. Resistance was defined as a failure to respond to at least 1 but not more than 3 adequate antidepressant trials, each taken for at least 6 weeks. After 4-6 weeks of open-label citalopram monotherapy (mean modal dose, 46 mg) to confirm nonresponse to a standard selective serotonin reuptake inhibitor (< 50% reduction in HAM-D-17), patients who were nonresponders were eligible for an additional 4-6 weeks of open-label risperidone augmentation therapy (mean modal doses, citalopram 52. The 62% of patients who achieved symptom resolution with risperidone augmentation (HAM-D-17 score ≤ 7 or CGI-S score of 1 or 2) were then randomized to 24 weeks of double-blind continuation treatment with risperidone augmentation of citalopram (mean modal doses, 1. A significant difference in median time to relapse was not found between groups continuing with risperidone augmentation and those who returned to citalopram monotherapy (102 days compared with 85 days; P=0. However, findings from post-hoc subgroup analyses performed on data from the risperidone trial indicated that level of resistance to antidepressant treatment may have been a mitigating factor. In the subgroup of participants who were “fully nonresponsive” (less than 25% reduction in HAM-D-17), time to relapse was significantly greater for risperidone augmentation (97 days) than placebo (56 days, P=0. Atypical antipsychotic drugs Page 105 of 230 Final Report Update 3 Drug Effectiveness Review Project Suicide and suicidal ideation Compared with placebo, no statistically significant advantage in reducing suicidal ideation or suicide was found for aripiprazole, risperidone, or extended-release quetiapine. Suicides and 456 suicidal ideation outcomes were found for aripiprazole in a poster that reported a pooled analysis based on data from two 6-week, placebo-controlled trials of adjunctive treatment in 433, 439 adults with a history of inadequate response to antidepressant medication. In the pooled 456 analysis of adjunctive aripiprazole (N=737) compared with placebo, there were no suicides in either group, nor did any patient demonstrate treatment-emergent suicidal ideation based on the criterion of a score of 5 or greater on item 10 of the MADRS (score of 6, “Explicit plans for suicide when there is an opportunity”). Incidence rates of treatment-emergent suicidal ideation were somewhat lower for aripiprazole (3. Rates of treatment-emergent, suicide-related, adverse events were 0% and 0. Both suicide-related adverse events in the placebo group were reported as suicidal ideation. There was also no significant difference between maintenance treatment with extended-release quetiapine or placebo monotherapy in suicidal ideation (data not 450 reported) based on findings from an unpublished trial. The effect of adjunctive risperidone on suicidal ideation was also evaluated in a small trial of 23 adults with severe depression (MADRS mean score of 35. In this trial, there was a trend toward risperidone augmentation superior to placebo (P=0. Functional capacity Functional capacity outcomes were found for aripiprazole, olanzapine, risperidone, and extended-release quetiapine. In all trials, functional capacity was measured based on the Sheehan Disability Scale (SDS). In the longest-term trial (unpublished, N=776), with up to 52 weeks of follow-up, maintenance treatment with extended-release quetiapine monotherapy was superior to 450 placebo in maintaining improvement in the SDS Total Score (data not reported). In adults with inadequate response to antidepressants, shorter-term evidence was found in 432, 433, 439 3 trials of aripiprazole given in combination with various antidepressants, 2 trials of 446 olanzapine given in combination with fluoxetine (in 1 publication), and in 1 trial of 438 risperidone given in combination with various antidepressants. The Family subscale was the only domain for which a statistically significant improvement was found compared with placebo across all trials of the 3 different atypical antipsychotics. Conversely, for the Work/School domain, no statistically significant improvements were found in any of the trials. On the Total Score, compared with placebo, improvements were significantly greater for adjunctive 439 438 aripiprazole in 1 of 3 trials and for adjunctive risperidone. Compared with placebo, 432, 439 significant improvements on the Social subscale were found in 2 of 3 trials of aripiprazole 438 and in the trial of risperidone.
Blinding usually is used in research studies that compare two or more types of treatment for an illness safe kamagra soft 100 mg. Second-generation antidepressants 182 of 190 Final Update 5 Report Drug Effectiveness Review Project Case series: A study reporting observations on a series of patients receiving the same intervention with no control group generic kamagra soft 100mg online. Case study: A study reporting observations on a single patient. Case-control study: A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls). Clinical diversity: Differences between studies in key characteristics of the participants, interventions or outcome measures. Clinically significant: A result that is large enough to affect a patient’s disease state in a manner that is noticeable to the patient and/or a caregiver. Cohort study: An observational study in which a defined group of people (the cohort) is followed over time and compared with a group of people who were exposed or not exposed to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective cohort study identifies subjects from past records and follows them from the time of those records to the present. Combination Therapy: The use of two or more therapies and especially drugs to treat a disease or condition. Confidence interval: The range of values calculated from the data such that there is a level of confidence, or certainty, that it contains the true value. The 95% confidence interval is generally used in Drug Effectiveness Review Project reports. If the report were hypothetically repeated on a collection of 100 random samples of studies, the resulting 95% confidence intervals would include the true population value 95% of the time. Confounder: A factor that is associated with both an intervention and an outcome of interest. Controlled clinical trial: A clinical trial that includes a control group but no or inadequate methods of randomization. Control group: In a research study, the group of people who do not receive the treatment being tested. The control group might receive a placebo, a different treatment for the disease, or no treatment at all. Convenience sample: A group of individuals being studied because they are conveniently accessible in some way. Convenience samples may or may not be representative of a population that would normally be receiving an intervention. Crossover trial: A type of clinical trial comparing two or more interventions in which the participants, upon completion of the course of one treatment, are switched to another. Direct analysis: The practice of using data from head-to-head trials to draw conclusions about the comparative effectiveness of drugs within a class or group. Results of direct analysis are the preferred source of data in Drug Effectiveness Review Project reports. Dosage form: The physical form of a dose of medication, such as a capsule, injection, or liquid. The route of administration is dependent on the dosage form of a given drug. Various dosage forms may exist for the same compound, since different medical conditions may warrant different routes of administration. Dose-response relationship: The relationship between the quantity of treatment given and its effect on outcome. In meta-analysis, dose-response relationships can be investigated using meta- regression. Double-blind: The process of preventing those involved in a trial from knowing to which comparison group a particular participant belongs. While double-blind is a frequently used term Second-generation antidepressants 183 of 190 Final Update 5 Report Drug Effectiveness Review Project in trials, its meaning can vary to include blinding of patients, caregivers, investigators, or other study staff. Double-dummy: The use of two placebos in a trial that match the active interventions when they vary in appearance or method of administrations (for example, when an oral agent is compared with an injectable agent). Effectiveness: The extent to which a specific intervention used under ordinary circumstances does what it is intended to do. Effectiveness outcomes: Outcomes that are generally important to patients and caregivers, such as quality of life, responder rates, number and length of hospitalizations, and ability to work. Data on effectiveness outcomes usually comes from longer-term studies of a “real-world” population. Effect size/estimate of effect: The amount of change in a condition or symptom because of a treatment (compared to not receiving the treatment). It is commonly expressed as a risk ratio (relative risk), odds ratio, or difference in risk. Efficacy: The extent to which an intervention produces a beneficial result under ideal conditions in a selected and controlled population. Equivalence level: The amount which an outcome from two treatments can differ but still be considered equivalent, as in an equivalence trial, or the amount which an outcome from treatment A can be worse than that of treatment B but still be considered noninferior, as in a noninferiority trial. Equivalence trial: A trial designed to determine whether the response to two or more treatments differs by an amount that is clinically unimportant. This lack of clinical importance is usually demonstrated by showing that the true treatment difference is likely to lie between a lower and an upper equivalence level of clinically acceptable differences. Exclusion criteria: The criteria, or standards, set out before a study or review. Exclusion criteria are used to determine whether a person should participate in a research study or whether an individual study should be excluded in a systematic review. Exclusion criteria may include age, previous treatments, and other medical conditions.
8 of 10 - Review by K. Boss
Votes: 342 votes
Total customer reviews: 342